Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Eisai Begins Marketing Diabetes II Drug in China

publication date: Sep 8, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eisai Pharma announced it has begun China marketing of Glufast®, a phenylalanine derived rapid-acting insulin secretagogue that stimulates insulin production. In 2007, Eisai in-licensed rights to sell Glufast in 10 ASEAN countries from Kissei Pharmaceutical Co., which discovered and developed the drug. It was approved by the SFDA in November 2009. More details....

Stock Symbol: (TSE: 4523)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...